St. Jude researchers identify ZMYND8 gene as regulator of T-cell exhaustion

Scientists at St. Jude Children's Research Hospital have identified the ZMYND8 gene as a primary regulator of CD8+ T-cell exhaustion. In studies published in the journal Nature, researchers found that constant exposure to tumors or chronic viral infections can cause T cells to become overstimulated and functionally impaired.

The ZMYND8 gene acts as a molecular brake by suppressing the expression of the interleukin-2 (IL-2) receptor. When this receptor is suppressed, T cells respond poorly to IL-2, a critical activation signal. By using CRISPR screening to delete the ZMYND8 gene in mouse models, the team observed improved control over melanoma and chronic viral infections.

Results indicated that removing the gene not only improves anti-tumor and anti-viral responses independently but also shows potential synergy when combined with existing immunotherapy approaches, such as checkpoint blockade. While these findings represent a potential new therapeutic target for treating pediatric solid tumors, the research is currently in the laboratory stage and has not yet been tested in human patients.